Navigation Links
Potential new drug for some patients with treatment-resistant lung cancer
Date:10/20/2013

BOSTON The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. In many cases, this is due to the cancer cells acquiring a second mutation called EGFR T790M, also known as the "resistance mutation."

"There are no approved therapies to treat lung cancer patients who develop the second mutation in the EGFR that stops the currently available medicines from working," said Susan Galbraith, M.D., Ph.D., head of the Oncology Innovative Medicines Unit at AstraZeneca. "The innovative breakthrough was finding a series of molecules that could target both the activating and resistance mutant forms of EGFR more potently than normal EGFR, which led to development of the new EGFR kinase inhibitor, AZD9291.

"AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines," she added.

The AstraZeneca scientists first showed that AZD9291 potently inhibited lung cancer cells with mutant EGFR, grown in lab dishes. They then tested the drug on mice bearing lung tumors with activating mutations and mice bea
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study identifies potential treatment for lethal childhood leukemia
2. McMaster researchers find potential for new uses of old drug
3. Army researcher develops potential vaccine carrier
4. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
5. New study of NIH funding allocations suggests potential efficiency gains
6. A closer look at PARP-1 reveals potential new drug targets
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Misuse of over-the-counter pain medication is potential health threat
10. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
11. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... 04, 2015 , ... assistPoint Partners, LLC is proud ... patient assistance programs. Through a secure web portal, assistPoint connects Life Sciences, Patients ... level, cloud-based application and workflow solution. This provides cancer center patient advocates, financial ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Bayco Products, Inc. announces ... to fit, for example, on hard hats that have a flip-up face shield. The ... allows users to work without having to remove their headlamp when raising or lowering ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Worldwide Power Products is expanding its reach in Texas. Effective July 1st of ... Systems North Texas generator division. With the North Texas acquisition, Worldwide Power ...
(Date:8/4/2015)... , ... August 04, 2015 , ... One of the ... to discuss his new book, The Pain Antidote , which provides strategies for ... Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction with ...
Breaking Medicine News(10 mins):Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:North Texas Acquisition Press Release 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3
... hospitals , , MONDAY, Dec. 17 (HealthDay News) -- A ... and anxiety that often follows major surgery, new research ... was equivalent to a [dose] of morphine, which was ... Hinshaw, professor of surgery and a member of the ...
... NEW MARTINSVILLE, W.Va., Dec. 17 In ... become tomorrow,s environmental,stewards, Bayer Corporation and the ... (UNEP RONA) today announced a new World,Environment ... Competition in Bayer MaterialScience New Martinsville partner,schools., ...
... OWINGS MILLS, Md., Dec. 17 Medifast, Inc.,(NYSE: ... has received approval to sell,Medifast Weight Control Centers ... available in 43 states. Medifast recently,received approval to ... Rhode Island and Virginia., "The Medifast Weight ...
... season is a,great opportunity to relax, spend time with family, ... the next 12 months. These top resolutions,offered by the American ... healthy new you in 2008., "Creating and sticking to ... you can give yourself this holiday season," said AMA,President, Ron ...
... a high volume of corrective surgeries show higher survival ... -- Babies with congenital heart defects are more likely ... the most experience in treating such cases, U.S. researchers ... figures from the 2003 Kids, Inpatient Database, which is ...
... Murtha, Chairman of the House Appropriations Subcommittee on Defense, this ... veterans blinded by war and for research to restore their ... gives the Man of Vision Award to an individual who ... of the challenges of vision loss. Among previous awardees have ...
Cached Medicine News:Health News:Massage Eases Pain, Anxiety After Surgery 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 3Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 4Health News:Medifast, Inc. Receives Approval to Sell Medifast Weight Control Centers Franchises in Seven Additional States 2Health News:AMA: Resolutions for a Healthy New You in the New Year 2Health News:Babies With Heart Defects Do Best at Hospitals With Most Experience 2Health News:Champion of blinded soldiers, Congressman Murtha, is Man of Vision 2
(Date:8/4/2015)... BEIJING , Aug. 4, 2015 Concord Medical ... a leading specialty hospital management solution provider and operator of ... China , today announced it will release ... the market closes on August 17, 2015. Management ... following day, at 8:00 a.m. EDT on August 18, 2015 ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... 4, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, today ... will present live at VirtualInvestorConferences.com on August 6, ... TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... online event where investors are invited to ask ...
Breaking Medicine Technology:Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3
... , May 10 Ferring Pharmaceuticals ... Women,s Health product portfolio with the acquisition of ... acid), a first-in-class, non-hormonal therapy indicated specifically for ... (HMB).  The company will initially market LYSTEDA in ...
... 10 Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), today announced the ... Mr. Macaluso replaces Dr. David Bar-Or, who remains the Chief Scientific Officer and ... Bar-Or have served on Ampio,s Board since the date of its acquisition of ... , , ...
Cached Medicine Technology:Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 2Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 3Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 4Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 5Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer 2
... The Perc NCircle® is designed to ... nephrolithotomy (PCNL). The Perc NCircle combines traditional ... NCircle nitinol tipless basket technology. The ... NCircle basket allows the surgeon to remove ...
... drainage from the ureteropelvic junction to ... packages. Intended for one-time use. CAUTION: ... Sof-Flex® stents must not remain indwelling ... stents must not remain indwelling more ...
... ACMI Classic Double Pigtail Ureteral ... pigtail design that maximizes migration. They ... added versatility and cost savings. ... Kit contains one Classic Double PigTail ...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection....
Medicine Products: